Stay updated with breaking news from Charlesm Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the...
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) has earned an average recommendation of “Buy” from the twelve ratings firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that […]
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) had its target price lowered by BMO Capital Markets from $187.00 to $130.00 in a report issued on Tuesday morning, The Fly reports. A number of other analysts also recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Mirati Therapeutics from $175.00 to […]
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of...